The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2-breast cancer

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3919-3930

  Fujiwara, Saori ^a   Yamamoto Ibusuk, Mutsuko ^a   Yamamoto, Yutaka ^a   Yamamoto, Satoko ^a   Tomiguchi, Mai ^a   Takeshita, Takashi ^a   Hayashi, Mitsuhiro ^a   Sueta, Aiko ^a   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

4ICD; Breast cancer; Endocrine therapy; HER4; Prognosis; Splicing variants

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB2 PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; ESTROGEN RECEPTOR;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; HER4 GENE; HER4 INTRACELLULAR DOMAIN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; VERY ELDERLY; BIOSYNTHESIS; BREAST TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROTEIN TERTIARY STRUCTURE;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECEPTOR, ERBB-4; RECEPTORS, ESTROGEN;

EID: 84903535635     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2002     Document Type: Article

References (29)

1. Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y and Iwase H. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Breast Cancer. 2012.
2. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP and Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2):259-268.
3. Pawlowski V, Revillion F, Hebbar M, Hornez L and Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000; 6(11):4217-4225.
4. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I and Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010; 126(2):545-562.
5. Hollmen M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schoffski P and Elenius K. Proteolytic processing of ErbB4 in breast cancer. PLoS One. 2012; 7(6):e39413.
6. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM and Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006; 66(12):6412-6420.
7. Vidal GA, Naresh A, Marrero L and Jones FE. Presenilindependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem. 2005; 280(20):19777-19783.
8. Veikkolainen V, Vaparanta K, Halkilahti K, Iljin K, Sundvall M and Elenius K. Function of ERBB4 is determined by alternative splicing. Cell Cycle. 2011; 10(16):2647-2657.
9. Maatta JA, Olli K, Henttinen T, Tuittila MT, Elenius K and Salmivirta M. Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor. BMC Cell Biol. 2009; 10:5.
10. Muraoka-Cook RS, Feng SM, Strunk KE and Earp HS, 3rd. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia. 2008; 13(2):235-246.
11. Ni CY, Murphy MP, Golde TE and Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001; 294(5549):2179-2181.
12. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L and Jones FE. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol. 2004; 167(3):469-478.
13. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK and Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growthpromoting autocrine signal in breast tumor cells. Cancer Res. 2006; 66(16):7991-7998.
14. Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA and Jones FE. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer. 2010; 9:150.
15. Thor AD, Edgerton SM and Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol. 2009; 175(5):1802-1809.
16. Tovey SM, Dunne B, Witton CJ, Cooke TG and Bartlett JM. HER4 in breast cancer: comparison of antibodies against intra-and extra-cellular domains of HER4. Breast Cancer Res. 2006; 8(2):R19.
17. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M and Huebner K. Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res. 2007; 13(20):6115-6121.
18. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P, Joensuu H, Isola J and Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 2005; 65(4):1384-1393.
19. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, Aqeilan RI and Elenius K. Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A. 2008; 105(11):4162-4167.
20. Sundvall M, Peri L, Maatta JA, Tvorogov D, Paatero I, Savisalo M, Silvennoinen O, Yarden Y and Elenius K. Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene. 2007; 26(48):6905-6914.
21. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M and Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000; 275(12):8641-8649.
22. Ferretti E, Di Marcotullio L, Gessi M, Mattei T, Greco A, Po A, De Smaele E, Giangaspero F, Riccardi R, Di Rocco C, Pazzaglia S, Maroder M, Alimandi M, Screpanti I and Gulino A. Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets. Oncogene. 2006; 25(55):7267-7273.
23. Paatero I, Lassus H, Junttila TT, Kaskinen M, Butzow R and Elenius K. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol. 2013; 129(1):179-187.
24. Nielsen TO, Sorensen S, Dagnaes-Hansen F, Kjems J and Sorensen BS. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. Br J Cancer. 2013; 108(11):2291-2298.
25. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R and Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008; 68(15):6387-6395.
26. Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA and Earp HS, 3rd. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol. 2009; 29(18):4935-4948.
27. Machleidt A, Buchholz S, Diermeier-Daucher S, Zeman F, Ortmann O and BrockhoffG. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients. BMC Cancer. 2013; 13:437.
28. Hollmen M, Maatta JA, Bald L, Sliwkowski MX and Elenius K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene. 2009; 28(10):1309-1319.
29. Junttila TT, Laato M, Vahlberg T, Soderstrom KO, Visakorpi T, Isola J and Elenius K. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res. 2003; 9(14):5346-5357.